Company Filing History:
2 out of 10 
2 out of 846 
1 out of 43 Years Active: 2009-2013
Title: Kiyotaka Kuzushima: Innovator in Cancer Immunotherapy
Introduction
Kiyotaka Kuzushima is a prominent inventor based in Nagoya, Japan. He has made significant contributions to the field of cancer immunotherapy, particularly in the development of peptide-based vaccines targeting Epstein-Barr virus-infected cells. With a total of three patents to his name, Kuzushima's work has the potential to impact cancer treatment significantly.
Latest Patents
Kuzushima's latest patents include groundbreaking research on cytotoxic T-cell epitope peptides that specifically attack Epstein-Barr virus-infected cells. His innovative approach involves introducing mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells. This method has demonstrated the induction of Epstein-Barr virus-specific cytotoxic T cells, which can recognize epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304. These cytotoxic T cells have shown the ability to inhibit the outgrowth of Epstein-Barr virus-infected B cells and lyse Epstein-Barr virus-infected NK lymphomas and NK cells. Another notable patent involves a peptide that can form a complex with an HLA-A2402 molecule, recognized by HLA-A2402-restricted cytotoxic T lymphocytes, making it useful as a cancer vaccine for epithelial cancer patients with HLA-A2402.
Career Highlights
Kuzushima has worked with notable organizations, including Aichi Prefecture and Otsuka Pharmaceutical Company, Limited. His career reflects a commitment to advancing cancer research and developing innovative therapeutic solutions.
Collaborations
Kuzushima has collaborated with esteemed colleagues such as Yoshinori Ito and Ayako Okamura. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Kiyotaka Kuzushima's contributions to cancer immunotherapy through his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for new treatment options for patients affected by cancer.